One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -2.49%) were lower by 4% as of 11 a.m. ET today. The move comes as the fallout from the sudden termination of its partnership with ...

In a video shared to TikTok via her page, @lucy52915, which has racked up more than 750,000 views, she revealed pictures of ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...